AbCellera Biologics Inc. (ABCL) stock
Close on Nov 11, 2026Market cap $3.66BP/E –Yield –
AbCellera Biologics Inc. grew revenue 92.1% to $67.86M over the twelve months to Sep 30, 2026. Free cash flow was -$32.85M. At the latest close the market valued the company at $3.66B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.66B
- P/E ratio
- –
- Price to sales
- 54.00
- Price to book
- 3.45
- Dividend yield
- –
- Free cash flow yield
- -0.90%
Fundamentals
- Revenue
- $67.86M
- Net income
- -$148.30M
- EPS, diluted
- -$0.48
- Free cash flow
- -$32.85M
- Book value per share
- $3.34
- Diluted shares
- 318M
Trading
- Next earnings
- Feb 23, 2027 (estimated, during market hours)
- Previous close
- $12.46
- Open
- $12.70
- Day's range
- $11.93 – $12.95
- Volume
- 2,874,323
- Average volume (20 days)
- 3,410,379
- Beta (5 years)
- 1.47
- 52-week range
- $2.75 – $15.02
- RSI (14 days)
- 48.2
- Volatility (1 year)
- 85.6%
- Relative volume
- 0.48×
- WACC
- 12.2%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABCL | S&P 500 | Difference | ABCL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.7% | -2.4% | −2.3 pts | ||
| 3 months | +22.4% | -1.2% | +23.6 pts | ||
| Year to date | +249.4% | +12.3% | +237.1 pts | ||
| 1 year | +198.0% | +12.4% | +185.6 pts | ||
| 3 years | +195.8% | +78.8% | +117.0 pts | +43.5% | +21.4% |
| 5 years | -20.6% | +75.2% | −95.8 pts | -4.5% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases AbCellera Biologics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Update
- Update
- News
About AbCellera Biologics
Pharmaceutical Preparations
AbCellera is a clinical-stage biotechnology company that discovers and develops antibody medicines for disease areas with high unmet medical needs. The company utilizes a vertically integrated technology platform that combines computational tools and laboratory research to discover antibodies from natural immune responses. Its internal pipeline features clinical-stage drug candidates, including ABCL635 for menopausal vasomotor symptoms and ABCL575 for atopic dermatitis, as well as preclinical candidates in autoimmunity and oncology. Additionally, the company collaborates with global biopharmaceutical and biotechnology partners to discover and advance therapeutic programs.
Company profile, executives and historyAbCellera Biologics stock: common questions
What is AbCellera Biologics's stock price?
ABCL closed at $11.95 on Nov 11, 2026, down 4.09% on the day. Over the past 52 weeks it traded between $2.75 and $15.02.
What is AbCellera Biologics's market cap?
AbCellera Biologics was worth $3.66B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ABCL's P/E ratio?
AbCellera Biologics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.48), so it has no meaningful P/E ratio.
How much revenue does AbCellera Biologics make?
AbCellera Biologics reported revenue of $67.86M for the twelve months to Sep 30, 2026, up 92.1% from a year earlier.
Does AbCellera Biologics pay a dividend?
No. AbCellera Biologics has not paid a cash dividend over the last twelve months.
When does AbCellera Biologics report earnings next?
AbCellera Biologics is expected to report Q4 FY2026 results on Feb 23, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ABCL stock performed over the past year?
Including dividends, ABCL returned +198.0% over the past year, against +12.4% for the S&P 500.
How many ABCL shares are sold short?
29M shares were sold short at the latest FINRA report, 12.26% of the float, or 8.5 days of average trading volume.
Who are AbCellera Biologics's competitors?
Companies most similar to AbCellera Biologics by business, industry and size include BCYC, ASMB, ENTA, WVE, RXRX.
See a number that looks wrong?